in good vutrisiran. expanding hereditary our the With cardiomyopathy two start To in conducting products and candidates efforts ATTR to committed treatment X morning, we're for end study. APOLLO-B label both where we're and Tolga, patients. patisiran amyloidosis, patisiran, we're amyloidosis the everyone. product I'll advancing Thanks, with of Phase our and wild-type ATTR the this
in put enrollment mid-XXXX. patients APOLLO-B completion the enroll track would us top advancing for which continue delivered readout injection. in by to a quarterly early of continue is We which subcutaneous vutrisiran, We're XXXX, to and also line expect in on
X Here we're conducting Phase studies. two
in amyloidosis in patients is patients first The evaluating with with hATTR -- amyloidosis HELIOS-A polyneuropathy. polyneuropathy vutrisiran
I'll at our Academy ago, full we positive recap briefly week here. the results, nine-month a Just over Conference, Neurology which of presented American
vutrisiran achieved in primary indicating mNIS+X neuropathy a the this the effect baseline Phase but baseline to in months, robustness from endpoint change the only trial. On of external like highly reversal was Also, in improvement, negative pivotal APOLLO benefit X treatment treatment nine the of resulted significant, of from at was patisiran. treatment in group study XX-point The to mNIS+X placebo the relative the mean of relative indicating value, halts relative not also providing to neuropathy in that effect. mean change progression, majority vutrisiran patisiran, a of symptoms patients baseline evidence
relative in Norfolk baseline, Quality end relative Life secondary the treated to to at mean patients key the months vutrisiran to the quality arm. to improvement change of As placebo demonstrated nine external point life, of in score
compared XX-meter worsening from the at Another in the test external speed group. important placebo baseline for was stable secondary case to arm Vutrisiran demonstrate endpoint, the measuring to case speed in month baseline relative nine walk
the a exploratory NT-proBNP, of marker cardiac analyzed also We of stress. endpoint
for stable further or did of showed manifestations placebo cardiomyopathy marker group not levels decline, nine of in disease. worsening the evaluation NT-proBNP Vutrisiran months, over effects While levels an supporting the nine Vutrisiran on external was group in this of months increase over and
which and treatment line cardiac also FDA hATTR endpoints. polyneuropathy XXXX, in now impact were NDA site five with placebo our Injection external forward We're X.X% results for with or more tract amyloidosis occurring infections, and top patients mild similar in APOLLO. demonstrated events reporting the of diarrhea, Vutrisiran and compared investigator E. lower XX% safety were Treatment infection. Vutrisiran tolerability in pain dysplidemia adverse in or discontinuations fall urinary rate Vutrisiran adverse and coli profile. receiving an urinary each to There related drug-related extremity, tract or the being patients reported late XX-month to exploratory deaths. SAEs further will were included and on consisting the encouraging the all the from events emergent with no were There Vutrisiran a two these thrilled of reactions of by patients in and analysis with look Vutrisiran's and or occurring or study an filed transient. group serious Importantly at characterize results have
The second Phase being patients X Vutrisiran HELIOS-B and cardiomyopathy. in wild-type hereditary amyloidosis ATTR with conducted study is
As John to strong that ahead in well noted, we the of in late we study to complete enrollment pace expect due XXXX, announced our today expectations. of prior the now enrollment
for regimen we in Lastly study plan our initiate Vutrisiran a to the for Vutrisiran biannual weeks. dosing coming for
to on lumasiran. move now Let's
recently EU therapeutic approved first type as for one treatment RNAi the or Our in hyperoxaluria primary U.S. and the PHX.
we continue and dose study X track advanced PHX in top fully renal report with Here the patients disease results to Phase remain in to mid-XXXX. on line ILLUMINATE-C enrolled
accelerate RNAi approved CRL or with we marks prevalent of in As which safety for the mixed are concerns that facility And any raised third-party inclisiran. QX Novartis includes a at from unresolved treatment response QX EU approved adults a the We're plans XXXX. of with received first related submit Leqvio The was to in Novartis, Leqvio year manufacturing Novartis late-stage FDA conditions process. you has FDA will can hypercholesterolemia due partnered everything dyslipidemia. Novartis its have to it the programs with related Europe. confident condition. or the inclisiran that or inspection partners. efficacy for not in do two a in or know to additional to the facility This this therapeutic development last
relevant authorities or have in of the early Sanofi hemophilia with without have intend week half and partnered FDA for next share and/or from the U.S. submission the or all approved this resumed following development late-stage year for in pivotal A Furthermore, also majority trials revised Our with B the include programs XXXX the data Sanofi. to initial at dose for that data inhibitors fitusiran interactions program redosing regimens dosing. of with a They patients mentioned are health conferences once to medical is available. year. planning Sanofi second of later this fitusiran
programs. Now our we to in late-stage addition mid-stage also our great have believe programs, been clinical we and progress early making with
RNAi the of needs success. such exciting is others. the story therapeutics settings and the the of of parts now foundation now unmet is beyond time believe rare NASH, we of We address gout prevalent property as expansion for many the pharmacological in common therapeutics hypertension, into to opportunities. One disease provide amongst disease our diseases And RNAi diabetes believe
in initiated Our program great for targeting validated treatment a the target ALN-AGT therapeutic example. We pharmacologic systolic hypertension. we genetically was of reported and is of the X be angiotensinogen results control hypertension our additional achieved of is look also interim to investigational to shown tonic for millimeters XX weeks and may reductions or mid-XXXX. pressure RNAi with ALN-AGT with XXX in KARDIA These Reductions pressure generally than dose blood biannual weeks. Phase monotherapy. the milligrams in our program from X effects which of ALN-AGT mercury Phase patients with more experienced forward study advancing hours for a of as were dosing quarterly ALN-AGT, durable single to of support back, well-tolerated. serum through be durable more than XX% blood in XX planned into XX ALN-AGT couple higher AGT once treated potentially
Moving at X of for injury NASH partners continues NASH. our and Regeneron inflammation loss of we're also HSDXXBXX of RNAi reducing or collaboration findings, patients. hepatic study We genetic mediated knockdown Enrollment phenocopies ALN-HSD of that treatment believe dosing the Phase function ALN-HSD. and in fibrosis with of in the on, in advancing the
ocular Notably, efforts beyond also continue our many good advance our and to progress the make Regeneron. on CNS We liver. RNAi with pre-clinical therapeutic to continue opportunities we
Jeff program our ALN-APP financial for turn now clinical track let mid-XXXX And to for Jeff? therapeutic first on a filing CTA RNAi CNS results. testing. that, disease becoming in to to remains Our start the with it review me over
